Persistent symptoms or activity impairment seen in more than 25 percent of children hospitalized with COVID-19, MIS-C
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, Aug. 12, 2022 (HealthDay News) -- At least two months after hospitalization with acute COVID-19 or multisystem inflammatory syndrome in children (MIS-C), more than 25 percent experience persistent symptoms or activity impairment, according to a study published online Aug. 12 in Pediatrics.
Aline B. Maddux, M.D., from the University of Colorado School of Medicine and Children's Hospital Colorado in Aurora, and colleagues conducted a multicenter, prospective observational cohort study in 25 U.S. pediatric hospitals to examine risk factors for postdischarge sequelae in children and adolescents (aged younger than 21 years) after hospitalization for acute COVID-19 or MIS-C. Two- to four-month survey data were available for 76.8 percent of 155 patients with acute COVID-19 and 78.8 percent of 203 patients with MIS-C.
The researchers found that 11 and 8 percent of patients with acute COVID-19 and MIS-C, respectively, had a readmission. Of those with acute COVID-19, 26.9 percent had persistent symptoms or activity impairment (22.7 and 14.3 percent, respectively), while 30.0 percent of those with MIS-C had persistent symptoms or activity impairment (20.0 and 21.3 percent, respectively). Persistent symptoms and activity impairment were associated with more organ systems involved among patients with acute COVID-19 (adjusted risk ratios, 1.29 and 1.37, respectively). Persistent symptoms occurred more often among patients with MIS-C and preexisting respiratory conditions, while activity impairment was more frequent among those with obesity (adjusted risk ratios, 3.09 and 2.52, respectively). New morbidities were rarely observed (9 and 1 percent among those with COVID-19 and MIS-C, respectively).
"These findings highlight the importance of postdischarge follow-up of these severely ill patients," the authors write.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on September 21, 2022
Read this Next
Other Trending Articles